Skip to main content
SpringerLink
Log in

Breast Cancer Brain Metastases: Achilles’ Heel in Breast Cancer Patients’ Care

  • Chapter
  • First Online:
Breast Cancer Research and Treatment

Part of the book series: Cancer Treatment and Research ((CTAR,volume 188))

Abstract

Brain metastases (BM) significantly affect the prognosis as well as the quality of life of breast cancer (BC) patients. Although advancements in neurosurgical and radiotherapy techniques improve local control and symptom management, BM remains associated with a poor prognosis. In addition, the efficacy of currently approved systemic therapies in central nervous system (CNS) compartment is still limited, especially after progression on local therapy. The blood-brain barrier (BBB) has been recognized as a mechanism of primary resistance to many chemotherapeutic agents and targeted therapies due to low drug penetration. Other mechanisms of primary and secondary resistance are still unclear and may vary across the BC subtypes. New small molecules have demonstrated efficacy in BM, in particular for the HER2-positive subtype, with a benefit in survival. A new era has begun in the field of BM, and many trials specifically designed for this population are currently ongoing. The BC research community needs to address this call with the final aim of improving the efficacy of systemic therapy in CNS compartment and ultimately preventing the occurrence of BM.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 109.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 139.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Sperduto PW, Mesko S, Li J, Cagney D, Aizer A, Lin NU, Nesbit E, Kruser TJ, Chan J, Braunstein S, Lee J, Kirkpatrick JP, Breen W, Brown PD, Shi D, Shih HA, Soliman H, Sahgal A, Shanley R, Mehta MP et al (2020) Beyond an updated graded prognostic assessment (breast GPA): a prognostic index and trends in treatment and survival in breast cancer brain metastases from 1985 to today. Int J Radiat Oncol Biol Phys 107(2):334–343. https://doi.org/10.1016/j.ijrobp.2020.01.051

  2. Soffietti R, Ahluwalia M, Lin N, Rudà R (2020) Management of brain metastases according to molecular subtypes. Nat Rev Neurol 16(10):557–574. https://doi.org/10.1038/s41582-020-0391-x

    Article  CAS  PubMed  Google Scholar 

  3. Bailleux C, Eberst L, Bachelot T (2021) Treatment strategies for breast cancer brain metastases. Br J Cancer 124(1):142–155. https://doi.org/10.1038/s41416-020-01175-y

    Article  PubMed  Google Scholar 

  4. Steeg PS (2021) The blood–tumour barrier in cancer biology and therapy. Nat Rev Clin Oncol 18(11):696–714. https://doi.org/10.1038/s41571-021-00529-6

    Article  PubMed  Google Scholar 

  5. Darlix A, Louvel G, Fraisse J, Jacot W, Brain E, Debled M, Mouret-Reynier MA, Goncalves A, Dalenc F, Delaloge S, Campone M, Augereau P, Ferrero JM, Levy C, Fumet J-D, Lecouillard I, Cottu P, Petit T, Uwer L, Bachelot T (2019) Impact of breast cancer molecular subtypes on the incidence, kinetics and prognosis of central nervous system metastases in a large multicentre real-life cohort. Br J Cancer 121(12):991–1000. https://doi.org/10.1038/s41416-019-0619-y

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Kuksis M, Gao Y, Tran W, Hoey C, Kiss A, Komorowski AS, Dhaliwal AJ, Sahgal A, Das S, Chan KK, Jerzak KJ (2021) The incidence of brain metastases among patients with metastatic breast cancer: a systematic review and meta-analysis. Neuro Oncol 23(6):894–904. https://doi.org/10.1093/neuonc/noaa285

    Article  PubMed  Google Scholar 

  7. Morris PG, Murphy CG, Mallam D, Accordino M, Patil S, Howard J, Omuro A, Beal K, Seidman AD, Hudis CA, Fornier MN (2012) Limited overall survival in patients with brain metastases from triple negative breast cancer. Breast J 18(4):345–350. https://doi.org/10.1111/j.1524-4741.2012.01246.x

    Article  PubMed  Google Scholar 

  8. Sperduto PW, Mesko S, Li J, Cagney D, Aizer A, Lin NU, Nesbit E, Kruser TJ, Chan J, Braunstein S, Lee J, Kirkpatrick JP, Breen W, Brown PD, Shi D, Shih HA, Soliman H, Sahgal A, Shanley R, Mehta MP (2020) Survival in patients with brain metastases: summary report on the updated diagnosis-specific graded prognostic assessment and definition of the eligibility quotient. J Clin Oncol 38(32):3773–3784. https://doi.org/10.1200/jco.20.01255

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Arvold ND, Oh KS, Niemierko A, Taghian AG, Lin NU, Abi-Raad RF, Sreedhara M, Harris JR, Alexander BM (2012) Brain metastases after breast-conserving therapy and systemic therapy: incidence and characteristics by biologic subtype. Breast Cancer Res Treat 136(1):153–160. https://doi.org/10.1007/s10549-012-2243-x

    Article  PubMed  Google Scholar 

  10. Ferraro E, Singh J, Patil S, Razavi P, Modi S, Chandarlapaty S, Barrio AV, Malani R, Mellinghoff IK, Boire A, Wen HY, Brogi E, Seidman AD, Norton L, Robson ME, Dang CT (2022) Incidence of brain metastases in patients with early HER2-positive breast cancer receiving neoadjuvant chemotherapy with trastuzumab and pertuzumab. npj Breast Cancer 8(1):37. https://doi.org/10.1038/s41523-022-00380-7

  11. Pestalozzi BC, Zahrieh D, Price KN, Holmberg SB, Lindtner J, Collins J, Crivellari D, Fey MF, Murray E, Pagani O, Simoncini E, Castiglione-Gertsch M, Gelber RD, Coates AS, Goldhirsch A (2006) Identifying breast cancer patients at risk for Central Nervous System (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG). Ann Oncol 17(6):935–944. https://doi.org/10.1093/annonc/mdl064

  12. Gradishar WJ, Moran MS, Abraham J, Aft R, Agnese D, Allison KH, Anderson B, Burstein HJ, Chew H, Dang C, Elias AD, Giordano SH, Goetz MP, Goldstein LJ, Hurvitz SA, Isakoff SJ, Jankowitz RC, Javid SH, Krishnamurthy J, Kumar R (2022) Breast cancer, version 3.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 20(6):691–722. https://doi.org/10.6004/jnccn.2022.0030

  13. Ramakrishna N, Anders CK, Lin NU, Morikawa A, Temin S, Chandarlapaty S, Crews JR, Davidson NE, Franzoi MAB, Kirshner JJ, Krop IE, Patt DA, Perlmutter J, Giordano SH (2022) Management of advanced human epidermal growth factor receptor 2–positive breast cancer and brain metastases: ASCO guideline update. J Clin Oncol 40(23):2636–2655. https://doi.org/10.1200/jco.22.00520

    Article  CAS  PubMed  Google Scholar 

  14. Morikawa A, Wang R, Patil S, Diab A, Yang J, Hudis CA, McArthur HL, Beal K, Seidman AD (2018) Characteristics and prognostic factors for patients with HER2-overexpressing breast cancer and brain metastases in the era of HER2-targeted therapy: an argument for earlier detection. Clin Breast Cancer 18(5):353–361. https://doi.org/10.1016/j.clbc.2017.12.009

    Article  CAS  PubMed  Google Scholar 

  15. Duchnowska R, Jassem J, Goswami CP, Dundar M, Gökmen-Polar Y, Li L, Woditschka S, Biernat W, Sosińska-Mielcarek K, Czartoryska-Arłukowicz B, Radecka B, Tomasevic Z, Stępniak P, Wojdan K, Sledge GW, Steeg PS, Badve S (2015) Predicting early brain metastases based on clinicopathological factors and gene expression analysis in advanced HER2-positive breast cancer patients. J Neurooncol 122(1):205–216. https://doi.org/10.1007/s11060-014-1704-y

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Patchell RA, Tibbs PA, Walsh JW, Dempsey RJ, Maruyama Y, Kryscio RJ, Markesbery WR, Macdonald JS, Young B (1990) A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med 322(8):494–500. https://doi.org/10.1056/nejm199002223220802

    Article  CAS  PubMed  Google Scholar 

  17. Mintz AH, Kestle J, Rathbone MP, Gaspar L, Hugenholtz H, Fisher B, Duncan G, Skingley P, Foster G, Levine M (1996) A randomized trial to assess the efficacy of surgery in addition to radiotherapy in patients with a single cerebral metastasis. Cancer Interdisc Int J Am Cancer Soc 78(7):1470–1476

    Google Scholar 

  18. Vecht CJ, Haaxma-Reiche H, Noordijk EM, Padberg GW, Voormolen JHC, Hoekstra FH, Tans JTJ, Lambooij N, Metsaars JAL, Wattendorff AR, Brand R, Hermans J (1993) Treatment of single brain metastasis: Radiotherapy alone or combined with neurosurgery. Ann Neurol 33(6):583–590. https://doi.org/10.1002/ana.410330605

  19. Brown PD, Ballman KV, Cerhan JH, Anderson SK, Carrero XW, Whitton AC, Greenspoon J, Parney IF, Laack NNI, Ashman JB, Bahary J-P, Hadjipanayis CG, Urbanic JJ, Barker FG, Farace E, Khuntia D, Giannini C, Buckner JC, Galanis E, Roberge D (2017) Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C/CEC·3): a multicentre, randomised, controlled, phase 3 trial. Lancet Oncol 18(8):1049–1060. https://doi.org/10.1016/S1470-2045(17)30441-2

  20. Kayama, T., Sato, S., Sakurada, K., Mizusawa, J., Nishikawa, R., Narita, Y., Sumi, M., Miyakita, Y., Kumabe, T., Sonoda, Y., Arakawa, Y., Miyamoto, S., Beppu, T., Sugiyama, K., Nakamura, H., Nagane, M., Nakasu, Y., Hashimoto, N., Terasaki, M., Group, J. C. O (2018) Effects of surgery with salvage stereotactic radiosurgery versus surgery with whole-brain radiation therapy in patients with one to four brain metastases (JCOG0504): a phase III, noninferiority, randomized controlled trial. J Clin Oncol 36(33):3282–3289. https://doi.org/10.1200/jco.2018.78.6186

    Article  CAS  Google Scholar 

  21. Vogelbaum MA, Brown PD, Messersmith H, Brastianos PK, Burri S, Cahill D, Dunn IF, Gaspar LE, Gatson NTN, Gondi V, Jordan JT, Lassman AB, Maues J, Mohile N, Redjal N, Stevens G, Sulman E, Bent M, v. d., Wallace, H. J., Schiff, D. (2022) Treatment for brain metastases: ASCO-SNO-ASTRO guideline. J Clin Oncol 40(5):492–516. https://doi.org/10.1200/jco.21.02314

    Article  CAS  PubMed  Google Scholar 

  22. Yamamoto M, Serizawa T, Shuto T, Akabane A, Higuchi Y, Kawagishi J, Yamanaka K, Sato Y, Jokura H, Yomo S, Nagano O, Kenai H, Moriki A, Suzuki S, Kida Y, Iwai Y, Hayashi M, Onishi H, Gondo M, Tsuchiya K (2014) Stereotactic radiosurgery for patients with multiple brain metastases (JLGK0901): a multi-institutional prospective observational study. Lancet Oncol 15(4):387–395. https://doi.org/10.1016/S1470-2045(14)70061-0

  23. Cao KI, Lebas N, Gerber S, Levy C, Le Scodan R, Bourgier C, Pierga JY, Gobillion A, Savignoni A, Kirova YM (2015) Phase II randomized study of whole-brain radiation therapy with or without concurrent temozolomide for brain metastases from breast cancer. Ann Oncol 26(1):89–94. https://doi.org/10.1093/annonc/mdu488

  24. Mehta MP, Wang D, Wang F, Kleinberg L, Brade A, Robins HI, Turaka A, Leahy T, Medina D, Xiong H, Mostafa NM, Dunbar M, Zhu M, Qian J, Holen K, Giranda V, Curran WJ (2015) Veliparib in combination with whole brain radiation therapy in patients with brain metastases: results of a phase 1 study. J Neurooncol 122(2):409–417. https://doi.org/10.1007/s11060-015-1733-1

    Article  CAS  PubMed  Google Scholar 

  25. Morikawa A, Grkovski M, Patil S, Jhaveri KL, Tang K, Humm JL, Holodny A, Beal K, Schöder H, Seidman AD (2021) A phase I trial of sorafenib with whole brain radiotherapy (WBRT) in breast cancer patients with brain metastases and a correlative study of FLT-PET brain imaging. Breast Cancer Res Treat 188(2):415–425. https://doi.org/10.1007/s10549-021-06209-4

    Article  CAS  PubMed  Google Scholar 

  26. Arvanitis CD, Ferraro GB, Jain RK (2020) The blood–brain barrier and blood–tumour barrier in brain tumours and metastases. Nat Rev Cancer 20(1):26–41. https://doi.org/10.1038/s41568-019-0205-x

    Article  CAS  PubMed  Google Scholar 

  27. Ballinger WE Jr, Schimpff RD (1979) An experimental model for cerebral metastasis: preliminary light and ultrastructural studies. J Neuropathol Exp Neurol 38(1):19–34. https://doi.org/10.1097/00005072-197901000-00003

    Article  PubMed  Google Scholar 

  28. Lockman PR, Mittapalli RK, Taskar KS, Rudraraju V, Gril B, Bohn KA, Adkins CE, Roberts A, Thorsheim HR, Gaasch JA, Huang S, Palmieri D, Steeg PS, Smith QR (2010) Heterogeneous blood-tumor barrier permeability determines drug efficacy in experimental brain metastases of breast cancer. Clin Cancer Res 16(23):5664–5678. https://doi.org/10.1158/1078-0432.Ccr-10-1564

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Lewis Phillips GD, Nishimura MC, Lacap JA, Kharbanda S, Mai E, Tien J, Malesky K, Williams SP, Marik J, Phillips HS (2017) Trastuzumab uptake and its relation to efficacy in an animal model of HER2-positive breast cancer brain metastasis. Breast Cancer Res Treat 164(3):581–591. https://doi.org/10.1007/s10549-017-4279-4

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Morikawa A, Peereboom DM, Thorsheim HR, Samala R, Balyan R, Murphy CG, Lockman PR, Simmons A, Weil RJ, Tabar V, Steeg PS, Smith QR, Seidman AD (2015) Capecitabine and lapatinib uptake in surgically resected brain metastases from metastatic breast cancer patients: a prospective study. Neuro Oncol 17(2):289–295. https://doi.org/10.1093/neuonc/nou141

    Article  CAS  PubMed  Google Scholar 

  31. Freedman RA, Gelman RS, Agar NYR, Santagata S, Randall EC, Gimenez-Cassina Lopez B, Connolly RM, Dunn IF, Van Poznak CH, Anders CK, Melisko ME, Silvestri K, Cotter CM, Componeschi KP, Marte JM, Moy B, Blackwell KL, Puhalla SL, Ibrahim N, Lin NU (2020) Pre- and postoperative neratinib for HER2-positive breast cancer brain metastases: translational breast cancer research consortium 022. Clin Breast Cancer 20(2):145-151.e142. https://doi.org/10.1016/j.clbc.2019.07.011

    Article  CAS  PubMed  Google Scholar 

  32. Sambade MJ, Prince G, Deal AM, Trembath D, McKee M, Garrett A, Keith K, Ramirez J, Midkiff B, Blackwell K, Sammons S, Leone JP, Brufsky A, Morikawa A, Brogi E, Seidman A, Ewend M, Carey LA, Moschos SJ, Anders C (2019) Examination and prognostic implications of the unique microenvironment of breast cancer brain metastases. Breast Cancer Res Treat 176(2):321–328. https://doi.org/10.1007/s10549-019-05211-1

    Article  PubMed  PubMed Central  Google Scholar 

  33. Zhang L, Zhang S, Yao J, Lowery FJ, Zhang Q, Huang WC, Li P, Li M, Wang X, Zhang C, Wang H, Ellis K, Cheerathodi M, McCarty JH, Palmieri D, Saunus J, Lakhani S, Huang S, Sahin AA, Yu D (2015) Microenvironment-induced PTEN loss by exosomal microRNA primes brain metastasis outgrowth. Nature 527(7576):100–104. https://doi.org/10.1038/nature15376

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Boogerd W, Dalesio O, Bais EM, van der Sande JJ (1992) Response of brain metastases from breast cancer to systemic chemotherapy. Cancer 69(4):972–980. https://doi.org/10.1002/1097-0142(19920215)69:4%3c972::aid-cncr2820690423%3e3.0.co;2-p

    Article  CAS  PubMed  Google Scholar 

  35. Fine RL, Chen J, Balmaceda C, Bruce JN, Huang M, Desai M, Sisti MB, McKhann GM, Goodman RR, Bertino JS Jr, Nafziger AN, Fetell MR (2006) Randomized study of paclitaxel and tamoxifen deposition into human brain tumors: implications for the treatment of metastatic brain tumors. Clin Cancer Res 12(19):5770–5776. https://doi.org/10.1158/1078-0432.Ccr-05-2356

    Article  CAS  PubMed  Google Scholar 

  36. Peereboom DM, Murphy C, Ahluwalia MS, Conlin A, Eichler A, Van Poznak C, Baar J, Elson P, Seidman AD (2014) Phase II trial of patupilone in patients with brain metastases from breast cancer. Neuro Oncol 16(4):579–583. https://doi.org/10.1093/neuonc/not305

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Cortés J, Rugo HS, Awada A, Twelves C, Perez EA, Im SA, Gómez-Pardo P, Schwartzberg LS, Diéras V, Yardley DA, Potter DA, Mailliez A, Moreno-Aspitia A, Ahn JS, Zhao C, Hoch U, Tagliaferri M, Hannah AL, O’Shaughnessy J (2017) Prolonged survival in patients with breast cancer and a history of brain metastases: results of a preplanned subgroup analysis from the randomized phase III BEACON trial. Breast Cancer Res Treat 165(2):329–341. https://doi.org/10.1007/s10549-017-4304-7

    Article  PubMed  PubMed Central  Google Scholar 

  38. Tolaney SM, Sahebjam S, Le Rhun E, Bachelot T, Kabos P, Awada A, Yardley D, Chan A, Conte P, Diéras V, Lin NU, Bear M, Chapman SC, Yang Z, Chen Y, Anders CK (2020) A phase II study of abemaciclib in patients with brain metastases secondary to hormone receptor-positive breast cancer. Clin Cancer Res 26(20):5310–5319. https://doi.org/10.1158/1078-0432.Ccr-20-1764

    Article  CAS  PubMed  Google Scholar 

  39. Conlan MG, de Vries EFJ, Glaudemans A, Wang Y, Troy S (2020) Pharmacokinetic and pharmacodynamic studies of elacestrant, a novel oral selective estrogen receptor degrader, in healthy post-menopausal women. Eur J Drug Metab Pharmacokinet 45(5):675–689. https://doi.org/10.1007/s13318-020-00635-3

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Leone JP, Emblem KE, Weitz M, Gelman RS, Schneider BP, Freedman RA, Younger J, Pinho MC, Sorensen AG, Gerstner ER, Harris G, Krop IE, Morganstern D, Sohl J, Hu J, Kasparian E, Winer EP, Lin NU (2020) Phase II trial of carboplatin and bevacizumab in patients with breast cancer brain metastases. Breast Cancer Res 22(1):131. https://doi.org/10.1186/s13058-020-01372-w

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Litton JK, Rugo HS, Ettl J, Hurvitz SA, Gonçalves A, Lee K-H, Fehrenbacher L, Yerushalmi R, Mina LA, Martin M, Roché H, Im Y-H, Quek RGW, Markova D, Tudor IC, Hannah AL, Eiermann W, Blum JL (2018) Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. N Engl J Med 379(8):753–763. https://doi.org/10.1056/NEJMoa1802905

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Robson ME, Tung N, Conte P, Im SA, Senkus E, Xu B, Masuda N, Delaloge S, Li W, Armstrong A, Wu W, Goessl C, Runswick S, Domchek SM (2019) OlympiAD final overall survival and tolerability results: olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Ann Oncol 30(4):558–566. https://doi.org/10.1093/annonc/mdz012

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Brenner AJ, Pandey R, Chiou J, Floyd J, Garcia M, Surapaneni P, Kaklamani V, Lathrop K, Crownover R, Caron JL, Tiziani S (2020) 373MO Delivery and activity of SN-38 by sacituzumab govitecan in CNS tumours. Ann Oncol 31:S401. https://doi.org/10.1016/j.annonc.2020.08.482

    Article  Google Scholar 

  44. Diéras V, Weaver R, Tolaney SM, Bardia A, Punie K, Brufsky A, Rugo HS, Kalinsky K, Traina T, Klein L, Loirat D, Lynce F, Daniel B, Ademuyiwa F, Hurvitz SA, Goldenberg DM, Hong Q, Olivo M, Itri LM, Carey L (2021) Abstract PD13–07: Subgroup analysis of patients with brain metastases from the phase 3 ASCENT study of sacituzumab govitecan versus chemotherapy in metastatic triple-negative breast cancer. Cancer Res 81(4_Supplement), PD13-07-PD13-07. https://doi.org/10.1158/1538-7445.Sabcs20-pd13-07

  45. von Minckwitz G, Procter M, de Azambuja E, Zardavas D, Benyunes M, Viale G, Suter T, Arahmani A, Rouchet N, Clark E, Knott A, Lang I, Levy C, Yardley DA, Bines J, Gelber RD, Piccart M, Baselga J (2017) Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer. N Engl J Med 377(2):122–131. https://doi.org/10.1056/NEJMoa1703643

    Article  Google Scholar 

  46. von Minckwitz G, Huang C-S, Mano MS, Loibl S, Mamounas EP, Untch M, Wolmark N, Rastogi P, Schneeweiss A, Redondo A, Fischer HH, Jacot W, Conlin AK, Arce-Salinas C, Wapnir IL, Jackisch C, DiGiovanna MP, Fasching PA, Crown JP, Geyer CE (2018) Trastuzumab emtansine for residual invasive HER2-positive breast cancer. N Engl J Med 380(7):617–628. https://doi.org/10.1056/NEJMoa1814017

    Article  Google Scholar 

  47. Martin M, Holmes FA, Ejlertsen B, Delaloge S, Moy B, Iwata H, von Minckwitz G, Chia SKL, Mansi J, Barrios CH, Gnant M, Tomašević Z, Denduluri N, Šeparović R, Gokmen E, Bashford A, Ruiz Borrego M, Kim S-B, Jakobsen EH, Charif M (2017) Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 18(12):1688–1700. https://doi.org/10.1016/S1470-2045(17)30717-9

    Article  CAS  PubMed  Google Scholar 

  48. Olson EM, Abdel-Rasoul M, Maly J, Wu CS, Lin NU, Shapiro CL (2013) Incidence and risk of central nervous system metastases as site of first recurrence in patients with HER2-positive breast cancer treated with adjuvant trastuzumab. Ann Oncol 24(6):1526–1533. https://doi.org/10.1093/annonc/mdt036

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Yardley DA, Tripathy D, Brufsky AM, Rugo HS, Kaufman PA, Mayer M, Magidson J, Yoo B, Quah C, Ulcickas Yood M (2014) Long-term survivor characteristics in HER2-positive metastatic breast cancer from registHER. Br J Cancer 110(11):2756–2764. https://doi.org/10.1038/bjc.2014.174

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Martin M, Holmes FA, Ejlertsen B, Delaloge S, Moy B, Iwata H, von Minckwitz G, Chia SKL, Mansi J, Barrios CH, Gnant M, Tomašević Z, Denduluri N, Šeparović R, Gokmen E, Bashford A, Ruiz Borrego M, Kim SB, Jakobsen EH, Chan A (2017) Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 18(12):1688–1700. https://doi.org/10.1016/s1470-2045(17)30717-9

    Article  CAS  PubMed  Google Scholar 

  51. Chan A, Moy B, Mansi J, Ejlertsen B, Holmes FA, Chia S, Iwata H, Gnant M, Loibl S, Barrios CH, Somali I, Smichkoska S, Martinez N, Alonso MG, Link JS, Mayer IA, Cold S, Murillo SM, Senecal F, Exte NETSG et al (2021) Final efficacy results of neratinib in HER2-positive hormone receptor-positive early-stage breast cancer from the phase III ExteNET trial. Clin Breast Cancer 21(1):80–91 e87. https://doi.org/10.1016/j.clbc.2020.09.014

  52. Saura C, Oliveira M, Feng Y-H, Dai M-S, Chen S-W, Hurvitz SA, Kim S-B, Moy B, Delaloge S, Gradishar W, Masuda N, Palacova M, Trudeau ME, Mattson J, Yap YS, Hou M-F, Laurentiis MD, Yeh Y-M, Chang H-T, Investigators, f. t. N. (2020) Neratinib Plus capecitabine versus lapatinib plus capecitabine in HER2-positive metastatic breast cancer previously treated with ≥ 2 HER2-directed regimens: phase III NALA trial. J Clin Oncol 38(27):3138–3149. https://doi.org/10.1200/jco.20.00147

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  53. Murthy RK, Loi S, Okines A, Paplomata E, Hamilton E, Hurvitz SA, Lin NU, Borges V, Abramson V, Anders C, Bedard PL, Oliveira M, Jakobsen E, Bachelot T, Shachar SS, Muller V, Braga S, Duhoux FP, Greil R, Winer EP (2020) Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer. N Engl J Med 382(7):597–609. https://doi.org/10.1056/NEJMoa1914609

    Article  CAS  PubMed  Google Scholar 

  54. Murthy RK, Loi S, Okines A, Paplomata E, Hamilton E, Hurvitz SA, Lin NU, Borges V, Abramson V, Anders C, Bedard PL, Oliveira M, Jakobsen E, Bachelot T, Shachar SS, Müller V, Braga S, Duhoux FP, Greil R, Winer EP (2019) Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer. N Engl J Med 382(7):597–609. https://doi.org/10.1056/NEJMoa1914609

    Article  PubMed  Google Scholar 

  55. Lin NU, Borges V, Anders C, Murthy RK, Paplomata E, Hamilton E, Hurvitz S, Loi S, Okines A, Abramson V, Bedard PL, Oliveira M, Mueller V, Zelnak A, DiGiovanna MP, Bachelot T, Chien AJ, O’Regan R, Wardley A, Winer EP (2020) Intracranial efficacy and survival with tucatinib plus trastuzumab and capecitabine for previously treated HER2-positive breast cancer with brain metastases in the HER2CLIMB trial. J Clin Oncol 38(23):2610–2619. https://doi.org/10.1200/jco.20.00775

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  56. Smith AE, Ferraro E, Safonov A, Morales CB, Lahuerta EJA, Li Q, Kulick A, Ross D, Solit DB, de Stanchina E, Reis-Filho J, Rosen N, Arribas J, Razavi P, Chandarlapaty S (2021) HER2 + breast cancers evade anti-HER2 therapy via a switch in driver pathway. Nat Commun 12(1):6667. https://doi.org/10.1038/s41467-021-27093-y

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  57. Ferraro E, Drago JZ, Modi S (2021) Implementing antibody-drug conjugates (ADCs) in HER2-positive breast cancer: state of the art and future directions. Breast Cancer Res 23(1):84. https://doi.org/10.1186/s13058-021-01459-y

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  58. Modi S, Saura C, Yamashita T, Park YH, Kim S-B, Tamura K, Andre F, Iwata H, Ito Y, Tsurutani J, Sohn J, Denduluri N, Perrin C, Aogi K, Tokunaga E, Im S-A, Lee KS, Hurvitz SA, Cortes J, Krop I (2019) Trastuzumab deruxtecan in previously treated HER2-positive breast cancer. N Engl J Med 382(7):610–621. https://doi.org/10.1056/NEJMoa1914510

    Article  PubMed  PubMed Central  Google Scholar 

  59. Bartsch R, Berghoff AS, Furtner J, Marhold M, Bergen ES, Roider-Schur S, Starzer AM, Forstner H, Rottenmanner B, Dieckmann K, Bago-Horvath Z, Haslacher H, Widhalm G, Ilhan-Mutlu A, Minichsdorfer C, Fuereder T, Szekeres T, Oehler L, Gruenberger B, Preusser M (2022) Trastuzumab deruxtecan in HER2-positive breast cancer with brain metastases: a single-arm, phase 2 trial. Nat Med 28(9):1840–1847. https://doi.org/10.1038/s41591-022-01935-8

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Breast Medicine Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA

    Emanuela Ferraro & Andrew D. Seidman

  2. Weill Cornell College of Medicine, New York, NY, USA

    Andrew D. Seidman

Authors
  1. Emanuela Ferraro
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Andrew D. Seidman
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Andrew D. Seidman .

Editor information

Editors and Affiliations

  1. Department of Medical Oncology, Mohammed VI University Hospital, Oujda, Morocco

    Ouissam Al Jarroudi

  2. Department of Medical Oncology, Mohammed VI University Hospital, Oujda, Morocco

    Khalid El Bairi

  3. Division of New Drugs and Early Drug Development, European Institute of Oncology IRCCS, Milan, Italy

    Giuseppe Curigliano

Rights and permissions

Reprints and permissions

Copyright information

© 2023 The Author(s), under exclusive license to Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Ferraro, E., Seidman, A.D. (2023). Breast Cancer Brain Metastases: Achilles’ Heel in Breast Cancer Patients’ Care. In: Al Jarroudi, O., El Bairi, K., Curigliano, G. (eds) Breast Cancer Research and Treatment. Cancer Treatment and Research, vol 188. Springer, Cham. https://doi.org/10.1007/978-3-031-33602-7_11

Download citation

  • DOI: https://doi.org/10.1007/978-3-031-33602-7_11

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-031-33601-0

  • Online ISBN: 978-3-031-33602-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation